Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Has Average Price Target of $7.50 According to Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $7.50.

A number of equities research analysts have recently weighed in on ZNTL shares. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, October 19th. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an “outperform” rating and a $8.00 target price for the company. Wells Fargo & Company began coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 30th. They issued an “equal weight” rating and a $5.00 target price on the stock. Jefferies Financial Group raised Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 14th. Finally, William Blair began coverage on Zentalis Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “outperform” rating on the stock.

Insider Activity

In other Zentalis Pharmaceuticals news, major shareholder Group Walters acquired 4,335,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were acquired at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the acquisition, the insider owned 17,844,973 shares in the company, valued at $62,457,405.50. The trade was a 32.09% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at $122,000. Eiger Wealth Management LLC grew its position in shares of Zentalis Pharmaceuticals by 33.8% in the 3rd quarter. Eiger Wealth Management LLC now owns 115,112 shares of the company’s stock valued at $319,000 after buying an additional 29,095 shares during the last quarter. Spark Investment Management LLC acquired a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth $61,000. Susquehanna Fundamental Investments LLC acquired a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth $126,000. Finally, Stonepine Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth $783,678.

Zentalis Pharmaceuticals Stock Down 2.8%

Shares of NASDAQ:ZNTL opened at $1.71 on Friday. The firm’s 50 day moving average price is $2.78 and its 200 day moving average price is $3.42. The stock has a market cap of $122.56 million, a price-to-earnings ratio of -0.88 and a beta of 1.91. Zentalis Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). On average, equities analysts anticipate that Zentalis Pharmaceuticals will post -2.15 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.